Over 20 in Stock
How does the RecoveryRx® technology work?
Pain is caused by inflammation, which is a swelling in the tissues of the body that then puts pressure on nerves causing pain. Chemical signals are also released by damaged cells in inflamed tissue that activate the nerves changing a chemical signal into an electrical impulse that causes pain for the body. Inflammation can be both acute, occurring immediately after an injury, or chronic (long lasting) inflammation which is unhealthy and can linger for months or years. Many diseases have been linked to chronic inflammation.
RecoveryRx® Core Technology
BioElectronics medical devices are pulsed shortwave devices that have the following specifications:
Working as an adjunct therapy, RecoveryRx® adds another dimension to multimodal approaches to pain management improving patient comfort. RecoveryRx® has been clinically shown to significantly reduce postoperative pain and the use of narcotic pain medication postoperatively, potentially reducing the incidence of adverse side effects associated with these drugs.
Pulsed shortwave therapy is widely used to treat pain in a wide array of medical applications, including musculoskeletal pain, edema, postoperative pain and the promotion of wound healing. These claims are backed by an extensive list of clinical publications and research.
PEMF therapy has been shown to have a number of therapeutic effects. These include reducing inflammation, increasing wound tensile strength, vasodilation, promoting angiogenesis and reducing postoperative pain. These effects result in a decreased need for postoperative pain medication and promotion of wound healing. Cell studies have shown gene families involved in tissue repair up-regulated after PEMF exposure (3). In mouse models of diabetic wounds, PEMF therapy has shown to increase dermal cell proliferation, increase tissue granulation and increase wound healing rates (4). And in human experimental wounds, PEMF treatment with an extended use device decreased healing times from 54 days in control to 39 days in the treated group (5), with advanced wound morphology also seen.